These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26197202)

  • 21. Dietary sodium: a therapeutic target in the treatment of hypertension and CKD.
    Sanghavi S; Vassalotti JA
    J Ren Nutr; 2013 May; 23(3):223-7. PubMed ID: 23611551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency.
    Juncos LI; Martín FL; Baigorria ST; Pasqualini ME; Fiore MC; Eynard AR; Juncos LA; García NH
    Nutrition; 2012 Sep; 28(9):e23-8. PubMed ID: 22698702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperphosphatemia in Chronic Kidney Disease: The Search for New Treatment Paradigms and the Role of Tenapanor.
    Cernaro V; Longhitano E; Casuscelli C; Peritore L; Santoro D
    Int J Nephrol Renovasc Dis; 2024; 17():151-161. PubMed ID: 38831770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KCa3.1: a new player in progressive kidney disease.
    Huang C; Pollock CA; Chen XM
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):61-6. PubMed ID: 25415613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically Based Biopharmaceutics Model (PBBM) of Minimally Absorbed Locally Acting Drugs in the Gastrointestinal Tract-Case Study: Tenapanor.
    Stamatopoulos K; Mistry N; Fotaki N; Turner DB; Swift B
    Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic Issues in treating hypertension in CKD.
    Sica DA
    Adv Chronic Kidney Dis; 2011 Jan; 18(1):42-7. PubMed ID: 21224029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing blood pressure in SHR with enalapril provokes redistribution of NHE3, NaPi2, and NCC and decreases NaPi2 and ACE abundance.
    Yang LE; Leong PK; McDonough AA
    Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1197-208. PubMed ID: 17652375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positive and Negative Aspects of Sodium Intake in Dialysis and Non-Dialysis CKD Patients.
    Nagasawa Y
    Nutrients; 2021 Mar; 13(3):. PubMed ID: 33809466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II clamp prevents the second step in renal apical NHE3 internalization during acute hypertension.
    Leong PK; Yang LE; Holstein-Rathlou NH; McDonough AA
    Am J Physiol Renal Physiol; 2002 Nov; 283(5):F1142-50. PubMed ID: 12372791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The MAURO study: baseline characteristics and compliance with guidelines targets.
    Leonardis D; Mallamaci F; Enia G; Postorino M; Tripepi G; Zoccali C;
    J Nephrol; 2012; 25(6):1081-90. PubMed ID: 23172127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic renal injury-induced hypertension alters renal NHE3 distribution and abundance.
    Yang LE; Zhong H; Leong PK; Perianayagam A; Campese VM; McDonough AA
    Am J Physiol Renal Physiol; 2003 May; 284(5):F1056-65. PubMed ID: 12554635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits of dietary sodium restriction in the management of chronic kidney disease.
    Krikken JA; Laverman GD; Navis G
    Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):531-8. PubMed ID: 19713840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal targets for blood pressure control in chronic kidney disease: the debate continues.
    Knight J; Wong MG; Perkovic V
    Curr Opin Nephrol Hypertens; 2014 Nov; 23(6):541-6. PubMed ID: 25295958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Posttranslational mechanisms associated with reduced NHE3 activity in adult vs. young prehypertensive SHR.
    Crajoinas RO; Lessa LM; Carraro-Lacroix LR; Davel AP; Pacheco BP; Rossoni LV; Malnic G; Girardi AC
    Am J Physiol Renal Physiol; 2010 Oct; 299(4):F872-81. PubMed ID: 20630932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should diuretics always be included as initial antihypertensive management in early-stage CKD?
    Segura J; Ruilope LM
    Curr Opin Nephrol Hypertens; 2009 Sep; 18(5):392-6. PubMed ID: 19561495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of sodium restriction and diuretic therapy for "resistant" hypertension in chronic kidney disease.
    Sinnakirouchenan R; Kotchen TA
    Semin Nephrol; 2014; 34(5):514-9. PubMed ID: 25416660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia.
    Yamada S; Tokumoto M; Tatsumoto N; Taniguchi M; Noguchi H; Nakano T; Masutani K; Ooboshi H; Tsuruya K; Kitazono T
    Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1418-28. PubMed ID: 24808541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.